Fall 2026
Posted on 8/14/2026
Develops medicines, vaccines, and consumer health
$22 - $43/hr
Durham, NC, USA
Hybrid
Hybrid role; relocation stipend may be available for hires living more than 50 miles from the assigned work location.
Bachelor's, Master's
See people who can refer or advise you
GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.
Company Size
10,001+
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
1891
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
GSK shares fall: mRNA flu vaccine advances to next study phase. September 1, 2026, 11:12 a.m. GSK is making progress with the development of an mRNA-based flu vaccine. As the British pharmaceutical company announced, a late-stage study for the vaccine candidate will begin in September. In a mid-stage study with younger and older adults, the drug showed stronger immune responses compared with standard and high-dose flu vaccines, according to GSK. The vaccine was generally well tolerated. "Given one billion flu cases and up to 650,000 deaths worldwide each year, there is a need for next-generation vaccine approaches," said Sanjay Gurunathan, head of research and development for vaccines and infectious diseases at GSK. Messenger RNA is the technology that Moderna as well as Pfizer and BioNTech used to develop their Covid-19 vaccines. In trading on the London Stock Exchange, GSK shares were temporarily down 0.51 percent at 18.44 GBP. DJG/DJN/mgo/hab By Adria Calatayud Selected leveraged products on GSK. With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on GSK. The base prospectus as well as the final terms and the basic information sheets can be obtained here: MM5AMJ, MM2M8P, MM18AM, MM2LN9, MM0WV7. Please also note the further information** regarding this advertisement. Risk warning: On average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.
GSK advances mRNA flu shot after Phase II success. 1,871.00p. 14:02 01/09/26. Drugmaker GSK said on Tuesday that it will move its mRNA seasonal flu vaccine candidate into Phase III after reporting positive Phase II results at the OPTIONS XIII influenza conference. 10,770.55. 5,869.38. 5,805.44. 23,612.26. 14:01 01/09/26. GSK said the candidate generated higher immune responses across all tested strains than both standard-dose and high-dose inactivated flu vaccines in younger and older adults, and was generally well tolerated. The Phase III study, due to begin in September, will be the first late-stage trial of an mRNA flu vaccine designed to target both haemagglutinin (HA) and neuraminidase (NA) - the two key surface antigens that help the virus bind and spread. Licensed flu vaccines primarily target HA, but GSK said growing evidence suggests adding NA could improve protection, reduce illness severity and help curb transmission. Sanjay Gurunathan, GSK's head of vaccines and infectious diseases R&D, said: "These promising data support the potential to better protect people from flu with a vaccine designed to target both HA and NA. With one billion flu cases worldwide each year and up to 650,000 deaths there is a need for next generation vaccine approaches. This result is a significant advance in our cutting-edge mRNA programme, and we look forward to starting phase III imminently." As of 1100 BST, GSK shares were down 0.27% at 1,848.50p. Reporting by Iain Gilbert at Sharecast.com
GSK Capital B.V., the Dutch financing arm of pharmaceutical company GSK plc, has priced a €3.5 billion four-tranche bond offering. The issuance includes an €850 million floating-rate note due 2028, priced at three-month Euribor plus 30 basis points. The offering also comprises a €1 billion four-year fixed-rate tranche due 2030 with a 3.50% coupon, €850 million of eight-year notes due 2034 carrying a 3.875% coupon, and €800 million of 11-year notes due 2037 with a 4.125% coupon. Settlement is scheduled for 7 September 2026. BNP Paribas and BofA Securities acted as global coordinators, whilst BNP Paribas, BofA Securities, HSBC, Santander and Standard Chartered Bank served as active bookrunners.
Noetik has reached its first milestone in a five-year collaboration with GSK, announced in January 2026. The San Francisco-based AI company successfully delivered and deployed its OCTO-VC model inference and fine-tuning capabilities, meeting GSK's testing criteria. Under the agreement, GSK holds a non-exclusive licence to Noetik's OCTO-VC models for non-small cell lung cancer and colorectal cancer, backed by $50 million in upfront capital and near-term milestone payments. The models are biological foundation models trained on hundreds of millions of spatially resolved human cells. GSK's teams are using OCTO-VC to perform virtual cell experiments, investigate patient stratification, and enrich their data with multimodal predictions. The partnership operates on a subscription-based framework rather than acquiring individual drug candidates.
Philanthropy and major gifts. Philanthropic giving and major gifts are crucial to the future of Child Bereavement UK, helping Child Bereavement UK to sustain its established services and build solid foundations for the charity to further evolve and innovate. Child Bereavement UK is extremely grateful to all its current donors who have joined Child Bereavement UK in ensuring that all families are able to access the support they need to rebuild their lives, when a child grieves or when a child dies. How can I give a gift? At Child Bereavement UK, Child Bereavement UK is very grateful for gifts of any size. Major gifts can be given to support its core work of supporting families and educating professionals, or as a restricted donation pertaining to a specific project or area of its work. Child Bereavement UK is able to give you guidance on gift aid and tax efficient giving and can accept most forms of charitable giving including through Trusts and Foundations, CAF, BACS, cheque and international donations via IBAN, Swift, CAF America and CAF American Donor Fund. The Patron's Pledge. For annual gifts, Child Bereavement UK has The Patron's Pledge which is supported by its Royal Patron HRH The Prince of Wales. The Patron's Pledge brings together philanthropic individuals and organisations who pledge their long-term support on an annual basis. This support is vital in enabling Child Bereavement UK to plan future growth with more certainty and increase its reach to communities where support is most needed. Child Bereavement UK will arrange an individual plan with you around when and how you would like to make your donations; these can be made annually, quarterly or via monthly direct debits. Child Bereavement UK had been keen supporters of Child Bereavement UK for several years when Child Bereavement UK made the decision to deepen its commitment by joining the Patron's Pledge. Child Bereavement UK liked the idea of giving a dedicated donation over a number of years, enabling the charity to plan better for the future. Over the years Child Bereavement UK has developed strong personal connections with the charity and regularly speak about how they're finding new ways to meet the challenges of its changing times. Current member of The Patron's Pledge who has committed 10 years of support The Pearl Pledge. The Pearl Pledge, founded to mark its 30th year, is for individuals and companies who want to make a multi-year commitment to Child Bereavement UK that will have a lasting impact for thousands of bereaved families across the UK. GSK is proud to be the Founder Corporate Patron for the Pearl Pledge as part of its ongoing support for Child Bereavement UK. Child Bereavement UK know the support Child Bereavement UK give has a huge impact on children and families who are bereaved and look forward to seeing the progress of the Pearl Pledge initiative. Its promise to you. Child Bereavement UK recognise that providing support at this level requires deep trust and belief in its work and a desire to make a real difference to people's lives when they are faced with the devastation of child bereavement. Child Bereavement UK promise to work in partnership with you as a valued supporter and you will enjoy a close connection with the charity through a dedicated contact who will keep you informed of charity developments and important events, and who will regularly share the positive difference Child Bereavement UK is making together to the lives of those Child Bereavement UK support. Child Bereavement UK will endeavour to offer interesting suggestions for ways to be involved with its work and engage with its beneficiaries and will work with you to help you to achieve any goals you may have through your support of Child Bereavement UK. How your support could make a difference £1,000 could provide free places for up to 40 teachers on a bereavement awareness webinar, helping them to gain understanding of grief and loss for children and young people as well as providing practical support and resources. £3,600 could enable Child Bereavement UK to respond to 100 calls to its freephone Helpline from bereaved families or the professionals who are supporting them, providing a listening ear, guidance, and support. £8,401 could enable Child Bereavement UK to run its bereavement services around the UK for a day, helping children, young people, and families to rebuild their lives after the devastation of bereavement. £19,500 could provide a year of bereavement support for 25 families, helping families to rebuild their lives when a child grieves or when a child dies. £36,000 could enable Child Bereavement UK to respond to 1,000 calls to its freephone Helpline from families seeking a lifeline after the death of someone important to them. £59,210 could support its work with schools for six months, equipping school staff and teachers with the tools and confidence to support their school community after the death of a pupil, parent, or teacher. At Child Bereavement UK, Child Bereavement UK help to rebuild lives - but Child Bereavement UK rely on generous people like you to provide the firm foundations, thank you so much for your incredible support. Get in touch. If you'd like to know more about giving a major gift, The Patron's Pledge or Pearl Pledge, please contact its fundraising team: Email: [email protected] Telephone: 01242 515 157